Trospium chloride: An effective option for medical treatment of bladder overactivity

International Journal of Clinical Pharmacology and Therapeutics

Volumn 38, Issue 5, 2000, Pages 223-234

  Fusgen I ^a   Hauri, D ^b  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Clinical trials; Detrusor hyperreflexia; Detrusor overactivity; Trospium chloride; Urge incontinence; Urodynamic measurements

Indexed keywords

OXYBUTYNIN; PLACEBO; TROSPIUM CHLORIDE;

BLADDER DYSFUNCTION; CLINICAL TRIAL; CYSTITIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENURESIS; HUMAN; MAJOR CLINICAL STUDY; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; URGE INCONTINENCE; URODYNAMICS;

EID: 0342699560     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP38223     Document Type: Review

References (58)

1. Abrams P et al 1998 Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 81: 801-810
2. Alloussi S, Baldauf J, Derouet H, Zwergel U, Meessen S 1991 Effect of trospium chloride, oxybutynin and propiverine on the interaction of acetylcholine with isolated preparations of the human urinary bladder. Invest Urol 4: 153-157
3. Alloussi S, Laval K-U, Eckert R, Ballering-Brühl B, Graße-Freese M, Bulitta M, Schäfer M 1998 Trospium chloride in patients with motor urge syndrome (detrusor instability): a double-blind, randomized, multicentre, placebo-controlled study. J Clin Res 1: 439-451
4. Antweiler HF, Lauterbach F, Lehmann HD, Übel H, Vogel G 1966 Zur Pharmakologie und Toxikologie von Azoniaspiranen in der Nortropin-bzw. Pseudonortropin-Reihe (Pharmacology and toxicology of azoniaspirans of the nortropin or pseudonortropin series). Arzneimittelforschung Drug Res 16: 1581-1591
5. Breuel HP, Mürtz G, Bondy S, Horkulak J, Giannetti BM 1993 Safety and tolerance of trospium chloride in the high dose range. Arzneimittelforschung Drug Res 43: 461-464
6. Brocklehurst JC 1993 Urinary incontinence in the community: analysis of a MORI poll. BMJ 306: 832-834
7. Cambell AJ, Reinken J, McCosh L 1985 Incontinence in the elderly: prevalence and prognosis. Age Ageing 14: 65-70
8. Cardozo L, Chapple R, Große-Freese M, Bulitta M, Lehmacher W, Strösser W, Schäfer M 2000 Efficacy of trospium chloride in patients with detrusor instability. Brit J Urol 85: in press
9. Diokno AC, Iles RL 1988 Harninkontinenz: Die verschwiegene Behinderung (Incontinence of urine: the silent handicap). Acron, Berlin
10. Drutz H et al 1997 Clinical efficacy and safety of tolterodine vs. oxybutynin and placebo in patients with unstable bladder. Abstract XV FIGO, World Congress of Gynecology and Obstetrics, August 3-8, Copenhagen, Denmark
11. 2+ concentration by anticholinergics in isolated myocytes from the dertrusor of the bladder). Aktuelle Urologie 26: 4-6
12. Elbadawi A, Yalla SV, Resnick NM 1993a Structural basis of geriatric voiding dysfunction. I. Methods of a correlative study and overview of the findings. J Urol 150: 1650-1656
13. Elbadawi A. Yalla SV, Resnick NM 1993b Structural basis of geriatric voiding dysfunction. II. Ageing detrusor: normal vs impaired contractility. J Urol 150: 1657-1667
14. Elbadawi A, Yalla SV, Resnick NM 1993c Structural basis of geriatric voiding dysfunction. III. Detrusor overactivity. J Urol 150: 1668-1680
15. Forth W, Henschler D, Rummel W, Starke K 1993 Allgemeine Pharmakologie und Toxikologie (General pharmacology and toxicology). BI Wissenschaftsverlag, Mannheim, pp 128-133
16. Fröhlich G, Burmeister S, Wiedemann A, Bulitta M 1998 Intravesikale Instillation von Trospiumchlorid, Oxybutynin und Verapamil zur Relaxation des Harnblasendetrusors (Intravesical instillation of trospium chloride, oxybutynin or verapamil to relax the detrusor of the bladder). Arzneimittelforschung Drug Res 48: 486-491
17. Herberg K-W 1999 Alltags- und Verkehrssicherheit unter Inkontinenz-Medikation: Neue Untersuchungen zum Sicherheitspotential urologischer Anticholinergika (Everyday life safety and safety while driving under treatment with incontinence drugs: New examinations regarding safety of anticholinergic drugs). Med Welt 50: 217-222
18. Herzog AR, Fultz N, Brock BM et al 1988 Urinary incontinence and psychological distress among older adults. Psychol Ageing 3: 115-121
19. Höfner K, Rettig K, Madersbacher H 1998 Reizblase und Dranginkontinenz: Trospiumchlorid bewährt sich bei Älteren (Trospium chloride helps in the treatment of irritable bladder and urge incontinence in the elderly). Geriatrie Praxis 10: 54-56
20. Höfner K 1998 Lebensqualität bei Harninkontinenz und Reizblasensymptomatk (Quality of life in urinary incontinence and irritable bladder). notabene medici 2: 69-70
21. Höfner K, Wiedemann A, Zumbé J. Füsgen I 1999 Neue Aspekte der Therapie der Harndranginkontinenz. Lebensqualität, Trinkverhalten und Versorgungssituation (New aspects of the management of urge incontinence. Quality of life, fluid intake and nursing care). Kassenarzt 12: 37-40
22. Kiesswetter H 1991 Konservative Therapie bei hyperaktivem Detrusor der Frau und besondere Aspekte beim Kind (Conservative therapy of detrusor hyperactivity in women and special aspects in children). Urologe B Insertion "Sicherheit in der Harninkontinenztherapie" 4: 5-6
23. Madersbacher H, Jähnig L, Rettig K 1995 Reizblasensymptomatik und Harndranginkontinenz, wirksame Therapie mit Spasmo-lyt Drageés (Irritable bladder symptoms and urge incontinence - an effective agent for urge (irritable bladder) syndrome). Allgemeinarzt 17: 501-503
24. Madersbacher H, Rettig 1997 Trospiumchlorid in der Allgemeinpraxis (Trospium chloride in general practice). Z Allg Med 73: 378-383
25. Madersbacher H, Stöhrer M, Mürtz G, Lauven G, Kuhn U 1993 Trospiumchlorid (Spasmo-lyt Dragees) - Ein wirksames Therapeutikum beim Urge-(Reizblasen-) Syndrom (Trospium chloride (Trospiumchlorid (Spasmo-lyt coated tablets) - an effective agent for urge (irritable bladder) syndrome). Urologe B 33: 89-93
26. Madersbacher H, Stöhrer M, Richter R, Burgdörfer H, Hachen HJ, Mürtz G 1995 Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyperreflexia. Br J Urol 75: 452-456
27. Madersbacher H, Stöhrer M, Richter R, Giannetti BM, Mürtz G 1991 Hochdosierte Applikation von Trospiumchlorid zur Therapie der Detrusorhyperreflexie (High-dose administration of trospium chloride in the treatment of detrusor hyperreflexia). Urologe A30: 260-263
28. McGrother C, Resnick M, Yalla SV, Kirschner-Hermanns R, Broseta E, Müller C, Welz-Barth A, Fischer GC, Mattelaer J, McGuire EJ 1998 Epidemiology and aetiology of urinary incontinence in the elderly. World J Urol 16: 3-9
29. McGuire EJ, Elbadawi A, Madersbacher H, Stanton SL, Thüroff JW, Füsgen I, Melchior H 1998 Statements of the committees of the WHO Consensus Conference, August 20, 1997. World J Urol 16: 1
30. Mutschler E 1999 Abstract Satellite Symposium - A new option for medical treatment of bladder overactivity: Fundamental aspects of the management of overactive bladder. XXIV EAU, Stockholm
31. Osca-Garcia JM, Martinez Agulló E, Conejero Sugrañes J, Jimenez Cruz JF 1997 Cloruro de trospio versus oxibutinina en el tratamiento de la vejiga hiperactiva. Estudio randomizado a doble ciego (A comparison of trospium chloride and oxybutynin in the treatment of the hyperactive bladder - A randomized double-blind study). Urod A 10: 40-44
32. Ouslander JG 1996 Lower urinary tract disorders in the elderly female. In: Raz S (ed) Female Urology (2nd ed). Saunders, Philadelphia, 219
33. Pannill FC III, Williams TF, Davis R 1988 Evaluation and treatment of urinary incontinence in long term care. J Am Geriatr Soc 36: 902-910
34. Peet SM, Castleden CM, McGrother CW 1995 Prevalence of urinary and fecal incontinence in hospitals and residential and nursing homes for elderly people. BMJ 311: 1063
35. Pietzko A, Dimpfel W, Schwantes U, Topfmeier P 1994 Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers. Eur J Clin Pharmacol 47: 337-343
36. Raz S, Erickson DR 1992 SEAPI QMM Incontinence qualification system. Neurourol Urodyn 11: 187-199
37. 3H]-trospium chloride in man. Part I and II, ICR. Madaus AG Report, Köln
38. Schulz H-U. Schürer M, Krumbiegel G 1999 A single dose two-way crossover investigation on the pharmacokinetics of trospium chloride under fasting condition and after concomitant intake of a high-fat meal. Scientific Monograph Spasmo-lyt 1999
39. Scientific Monograph Spasmo-lyt 1999
40. Seidel D, Özman AS, Hülsbusch R 1990 Blasenstörungen bei multipler Sklerose (Bladder disorders in multiple sclerosis). Medwelt 41: 1053-1055
41. Seliger-Heger B 1997 Behandlung der Strahlenzystitis mit Trospiumchlorid (Treatment of postirradiation cystitis with trospium chloride). Kassenarzt 11: 49
42. Stöhrer M, Bauer P, Giannetti BM, Richter R, Burgdörfer H, Mürtz G 1991 Effect of trospium chloride on urodynamic parameters in patients with detrusor hyperreflexia due to spinal cord injuries. A multicentre placebo-controlled double-blind trial. Urol Int 47 (3): 138-143
43. Stöhrer M, Bersch U, Göcking K, Schürch B, Kramer G 1998 Dose finding study for treatment of detrusor hyperreflexia by trospium chloride. 37th Annual Scientific Meeting of the International Medical Society of Paraplegia. Foz do Iguacu, Brazil, June 18-20
44. Suzuki T 1990 Effects of trospium chloride on lower urinary tract function. Hinyo Kiyo (Acta Urol Jpn) 36: 1047-1051
45. Thomas TM, Plymat KR, Blannin J, Meade TW 1980 Prevalence of urinary incontinence. BMJ 281: 1243-1245
46. Thüroff JW, Chartier-Kastler E, Corcus J, Humke J, Jonas U, Palmtag H, Tanagho EA 1998 Medical treatment and medical side-effects in urinary incontinence in the elderly. World J Urol 16: S48-61
47. Ückert S, Stief CG, Odenthal KP, Becker AJ, Truss MC, Jonas U 1998 Comparison of the effects of various spasmolytic drugs on isolated human and porcine detrusor smooth muscle. Arzneimittelforschung Drug Res 48: 836-839
48. Ückert S 1999 Personal communication.
49. Van Kerrebroeck PEVA et al 1997 Clinical efficacy and safety of tolterodine compared to oxybutynin in patients with overactive bladder. Abstract ICS '97, 27th Annual Meeting (International Continence Society), September 23-26, 1997, Yokohama, Japan
50. Vetter NT, Dee AJ, Victor CR 1981 Urinary incontinence in the elderly at home. Lancet II: 1275-1277
51. Wagner TH, Hu T-W 1998 Economic costs of urinary incontinence. Urology 51: 355-361
52. Welz-Barth A, Füsgen I 1998 Tabu-Erkrankung Harninkontinenz - Ergebnisse einer Praxiserhebung (Incontinence of urine - a taboo disease - results of a survey in general practice). Geriatrie Forsch 8: 143-148
53. Wiedemann A, Kracht H 1997 Erste Erfahrungen mit Trospiumchlorid bei postoperativer Reizblasensymptomatik. (First results with trospium chloride in post-operative irritable bladder symptoms). Med Welt 48: 456-457
54. Wiedemann A, Monser C, Braun W, Zumbe J 1998a Sozioökonomische Aspekte der Harninkontinenz (Socio-economic aspects of urinary incontinence). Urologe B 38: 154-159
55. Wiedemann A, Zumbe J, Rettig K, Madersbacher H 1998b Therapie der kindlichen Harninkontinenz mit Trospiumchlorid (Therapy of childhood incontinence with trospium chloride). Urologe B 38: 531-534
56. Wiedemann A, Zumbè J, Füsgen I 1999 Harndranginkontinenz: Anticholinerge Therapie ist effizient und reduziert Kosten (Urge incontinence: anticholinergic therapy is efficient and reduces costs). Allgemeinarzt 21: 1109-1112
57. Wymann IF 1997 The "costs" of urinary incontinence. Eur Urol 32 (Suppl 2): 13-19
58. Zerres K, Zaigler M, Rietbrock S, Weyhenmeyer R, Krumbiegel G, Fuhr U 1998 Pharmacokinetics of single- and multiple-dose trospium chloride in elderly volunteers using a replicative design. NaunynSchmiedebergs Arch Pharmacol 357 (Suppl): R 175